Loading data for CELC — first visit, this takes a few seconds.
Celcuity Inc.
83.45 -2.04 (-2.39%)
- Marktkapitalisierung
- $4.09B
- Volumen
- 863K
- Nächster Ergebnistermin
- Nov 11, 2026
Celcuity Inc. (CELC) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $0 | n/a | n/a |
| EPS | -$1,07 | +$0,01 | -15.05% |
Kennzahlen
- Geld
- 61.14
- Marktkapitalisierung
- 4.09B
- Umsatz (TTM)
- n/a
- Nettogewinn (TTM)
- -226M
- 0.20
- -4.3
- n/a
- -1044.12
- KBV (TTM)
- -320.04
- KUV (TTM)
- n/a
- Termin Quartalszahlen
- Nov 11, 2026
- Brief
- 86.53
- Volumen
- 862,736
- Ø Vol. (20D)
- 1,214,490
- Eröffnung
- 86.38
- Vortagesschluss
- 85.49
- Tagesspanne
- 83.23 - 87.01
- 52-Wk Range
- 44.42 - 151.02
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- n/a
Über Celcuity Inc.
Profil ansehen →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Branche Biotechnology
Sektor Healthcare
IPO Datum Sep 20, 2017
Mitarbeiter 155
Börse NasdaqCM
Tickersymbol CELC
Website https://www.celcuity.com